15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 4 firms covering BioLife Solutions Inc, 0 rate it Buy or better, 4 sit at Hold, and 0 rate it Sell or worse, a hold consensus. Targets are tightly clustered, $32.00 to $32.00, so the covering firms are broadly aligned. The average target of $32.00 is roughly in line with the current $31.95. The rating mix has stayed broadly stable, with Buy-side ratings easing from 1 to 0 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.07 next quarter toward $0.33 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 ratings
Hold
Strong Buy00%
Buy00%
Hold4100%
Sell00%
Strong Sell00%
Based on 4 analysts giving stock ratings to BioLife Solutions Inc.
As of Jul, 0 of 4 firms rate BLFS a Buy (4 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
BLFS EPS & revenue forecast
EPS · NEXT QUARTER
$0.07
Range $0.07 – $0.07 · 1 analysts · +67% YoY
Next period, 1 analysts expect BioLife Solutions Inc to earn $0.07 a share (range $0.07 – $0.07), versus $0.04 a year earlier. Full-year consensus is $0.25, growing to $0.33 the year after.
REVENUE · NEXT QUARTER
$28.9M
Range $28.6M – $29.3M · 1 analysts · +3% YoY
Revenue is expected to reach $28.9M (range $28.6M – $29.3M), +2.9% year-over-year. Full-year consensus is $114.0M, rising to $134.6M next year.
Top analysts covering BioLife Solutions Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on BLFS.
#1
Yi Chen
HC Wainwright & Co. · Rank #238
Hold
$31.00-3.0% to target
Overall win rate
34%
+ Follow
#2
RW
Robert Wasserman
Benchmark · Rank #259
Buy
$30.00-6.1% to target
Overall win rate
39%
+ Follow
#3
Paul Knight
Keybanc · Rank #296
Buy
$33.00+3.3% to target
Overall win rate
32%
+ Follow
#4
Jason McCarthy
Maxim Group · Rank #360
Hold
No targeton BLFS
Overall win rate
30%
+ Follow
#5
MH
Matt Hewitt
Craig-Hallum
Hold
$31.00-3.0% to target
Coverage
—
+ Follow
BLFS stock forecast FAQ
What is BLFS's average 12-month price target?+
The 1 analysts with a live target average $32.00 for BioLife Solutions Inc over the next 12 months, ranging from a $32.00 high to a $32.00 low.
Is BLFS stock a Buy, Sell or Hold right now?+
The current consensus is Hold. Of the 4 analyst ratings, 0 are Buy or Strong Buy, 4 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover BLFS?+
4 analysts have an active rating on BioLife Solutions Inc, and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering BLFS?+
Among analysts who currently cover BLFS, Yi Chen of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #238). Their current call is Hold with a $31.00 target.
What is BioLife Solutions Inc's projected EPS for next quarter?+
The consensus estimate is $0.07 per share (range $0.07 – $0.07) across 1 analysts. Full-year EPS is projected at $0.25, rising to $0.33 the following year.
How much revenue is BioLife Solutions Inc expected to report next quarter?+
Consensus revenue is $28.9M (range $28.6M – $29.3M). Full-year revenue is projected at $114.0M, growing to $134.6M next year.
Have analysts been upgrading or downgrading BLFS lately?+
As of Jul, 0 of 4 firms rate BLFS a Buy (4 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their BLFS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
